The Medical Research Council has invested £50 million in a new programme aimed at improving treatments for mitochondrial diseases, a group of genetic disorders that affect around one in 5,000 people. The funding supports the creation of the MRC Centre of Research Excellence in Mitochondrial Genome Therapeutics, which will bring together experts from several disciplines to better understand how mutations in mitochondrial DNA cause disease and to translate that knowledge into therapies.
Why mitochondrial disease research matters
Mitochondrial diseases currently have no cure, and the burden on patients and families remains significant. According to the MRC, these disorders can lead to severe disability, progressive decline and premature death. The council also said mtDNA mutations are increasingly linked to neurodegeneration, metabolic disease, cardiovascular failure and age-related deterioration.
The new centre is designed to build a long-term UK research platform with the scale, expertise and infrastructure needed to position the country as a global leader in mitochondrial genome therapeutics. Project lead Professor Michal Minczuk of the University of Cambridge said the programme aims to create the scientific foundations for entirely new therapeutic strategies and offer renewed hope to affected families.
A UK-led network with international partners
Led by the University of Cambridge, the centre will work with the University of Birmingham, The University of Manchester, Heidelberg University, the University of Queensland and the Imagine Institute in Paris. It will also collaborate with charities including the Lily Foundation and with industry partners worldwide.
Dr Ceri Williams, Executive Director of Challenge Led Themes at MRC, said the UK has already played a leading role in mitochondrial science, including the development of mitochondrial replacement therapy to prevent the inheritance of mtDNA mutations. She said the new centre builds on that foundation and could transform prevention, detection and treatment while improving outcomes for patients and protecting families affected by the disease.
What comes next
The initiative will also embed patient perspectives from the outset, with the Lily Foundation saying its role will help ensure family priorities shape the research and support the next generation of scientists. The announcement marks a further step in the UK’s effort to turn basic genetic research into practical medical advances, particularly in areas where treatment options remain limited.
For medical researchers, the project signals a major long-term investment in one of the more complex areas of inherited disease research, with the hope that deeper understanding of mitochondrial genome mutations will eventually lead to better therapies for patients in the UK and beyond.
Photo source: AI-generated or edited image
